Seribantumab clinical trials
Also written MM-121 and SAR256212.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses seribantumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 3 |
| 2011 | 4 |
| 2015 | 2 |
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 1
Merrimack Pharmaceuticals (8) · Elevation Oncology (3) · Ottawa Hospital Research Institute (1) · Sanofi (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses seribantumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid TumorsTerminatedPhase 2Elevation OncologyNCT04383210Written as SeribantumabHow we know
- Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using SeribantumabCompletedPhase 2Ottawa Hospital Research InstituteNCT04790695Written as SeribantumabHow we know
- A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLCTerminatedPhase 2Elevation OncologyNCT02387216Written as MM-121How we know
- Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast CancerTerminatedPhase 2Elevation OncologyNCT03241810Written as SeribantumabHow we know
- Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibTerminatedPhase 1Merrimack PharmaceuticalsNCT02538627Written as MM-121How we know
- A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast CancersCompletedPhase 1Merrimack PharmaceuticalsNCT01209195Written as MM-121How we know
- A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced CancersCompletedPhase 1Merrimack PharmaceuticalsNCT01451632Written as MM-121How we know
- Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary TreatmentCompletedPhase 1Merrimack PharmaceuticalsNCT00734305Written as MM-121How we know
- A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung CancerCompletedPhase 1/2Merrimack PharmaceuticalsNCT00994123Written as MM-121How we know
- Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast CancerCompletedPhase 2Merrimack PharmaceuticalsNCT01151046Written as MM-121How we know
- A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian CancersCompletedPhase 2Merrimack PharmaceuticalsNCT01447706Written as MM-121How we know
- A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast CancerCompletedPhase 2Merrimack PharmaceuticalsNCT01421472Written as MM-121How we know
- A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor CancersCompletedPhase 1SanofiNCT01436565Written as MM-121 (SAR256212)How we know
Given beside what is tested · 1 — seribantumab is usual care or a partner of the new treatment
Codes
What other systems call seribantumab · ClinicalTrials.gg INT000024
- MeSH (NLM) C000589319seribantumabOne source NLM
- UNII (FDA) 1N3L70MDFXSERIBANTUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q19946112seribantumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78859SeribantumabOne source FDA
- DrugBank DB11857One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000589319 | seribantumab | One source NLM |
| UNII (FDA) | 1N3L70MDFX | SERIBANTUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q19946112 | seribantumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78859 | Seribantumab | One source FDA |
| DrugBank | DB11857 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.